Vertex Pharmaceuticals gets EU nod to expand label for cystic fibrosis treatment

Zerbor/iStock via Getty Images Vertex Pharmaceuticals ( NASDAQ: VRTX ) said on Monday that the European Commission approved a label expansion for Kaftrio in a combination with ivacaftor to treat cystic fibrosis for a different patient group. With this approval , the indication includes all patients above 2.